4502 — Takeda Pharmaceutical Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeLarge CapMomentum Trap

Market Cap
¥10tn
Enterprise Value
¥14tn
Revenue
¥5tn

Annual income statement for Takeda Pharmaceutical, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Yuho
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	3,569,006	4,027,478	4,263,762	4,581,551	4,505,720
Cost of Revenue
Gross Profit	2,462,160	2,783,781	2,843,309	3,002,819	2,937,490
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	3,122,275	3,494,185	4,014,490	4,224,494	4,322,459
Operating Profit	446,731	533,293	249,272	357,057	183,261
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	302,571	375,090	52,791	175,084	-142,355
Provision for Income Taxes
Net Income After Taxes	230,166	317,038	144,197	108,143	-152,125
Minority Interest
Net Income Before Extraordinary Items
Net Income	230,059	317,017	144,067	107,928	-152,389
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	230,059	317,017	144,067	107,928	-152,390
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	199	244	175	148	101
Dividends per Share